Description

MK-2866 (Ostarine) Capsules: Industrial Grade Research Chemical

 

Product Details Table

 

---

MK-2866 (Ostarine) Capsules | Selective Androgen Receptor Modulator (SARM) | BioSynLab

BioSynLab presents pharmaceutical-grade MK-2866 (Ostarine) in convenient capsule formulation for advanced androgen receptor research and tissue-selective anabolic studies. As one of the most extensively characterized SARMs in the scientific literature, Ostarine serves as a critical reference compound for investigating androgen receptor (AR) partial agonism, anabolic/androgenic separation, and therapeutic applications in muscle wasting and osteoporosis research.

Chemical Architecture & SARM Mechanism

MK-2866 (Ostarine, Enobosarm) is a non-steroidal selective androgen receptor modulator featuring a distinctive bicyclic aryl propionamide scaffold:

Structural Features:

• Aryl Propionamide Core: Non-steroidal structure providing AR binding without steroidal side effects
• Trifluoromethyl Substitution: Electron-withdrawing group enhancing metabolic stability and receptor affinity
• Nitro/Amino Substitution Pattern: Critical pharmacophore for SARM selectivity
• Cyanide Substitution: Contributes to binding specificity and tissue selectivity

Mechanism of Action:

• Androgen Receptor Agonist: Binds AR with high affinity (Ki ~3.5 nM)
• Tissue Selectivity: Anabolic effects in muscle and bone with reduced androgenic activity in prostate and sebaceous glands
• Partial Agonism: Demonstrates partial agonist activity compared to full agonists (testosterone, DHT)
• Non-Steroidal: Avoids 5α-reductase and aromatase metabolism

Physicochemical Properties:

• Molecular weight: 389.33 g/mol
• Calculated LogP: 3.4 (moderate lipophilicity)
• pKa: Non-ionizable (neutral molecule)
• Melting point: 70-75°C (amorphous solid)
• Chirality: Racemic mixture (R- and S-enantiomers)

Capsule Formulation & Pharmaceutical Engineering

Our MK-2866 capsules utilize precision formulation technology:

Excipient Composition:

• Active Pharmaceutical Ingredient: MK-2866 – 10mg, 20mg, or 25mg
• Diluent: Microcrystalline cellulose (Avicel PH-102) – 100-250mg
• Glidant: Talc (pharmaceutical grade) – 2-5mg
• Lubricant: Magnesium stearate – 1-3mg

Capsule Specifications:

Quality Attributes:

• Content uniformity: RSD <6% (USP <905>)
• Weight variation: Meets USP <905> criteria
• Disintegration: <30 minutes (USP <701>)
• Dissolution: >80% in 45 minutes (simulated gastric fluid)

Packaging Options:

• HDPE bottles: 30, 60, 90 count with desiccant canister
• Blister packs: 10 capsules per sheet, child-resistant
• Bulk packaging: 500, 1000 count for institutional orders

Analytical Characterization & Quality Verification

Each BioSynLab MK-2866 batch undergoes comprehensive analytical profiling:

Chromatographic Analysis:

• HPLC-UV (220nm): ≥99.0% purity by area normalization
• Chiral HPLC: Enantiomeric ratio (racemic mixture, ~1:1)
• Related substances: <1.0% total impurities
• Residual solvents: Meets ICH Q3C (methanol, ethanol, acetonitrile, hexane)

Mass Spectrometry:

• LC-MS/MS: [M+H]⁺ at m/z 390.1, characteristic fragmentation pattern
• High-Resolution MS: Exact mass confirmation <5 ppm deviation

Nuclear Magnetic Resonance (NMR):

• ¹H NMR (500MHz, DMSO-d₆):
  • Aromatic protons: δ 6.8-7.6 (m, 8H)
  • Amide NH: δ 8.45 (br s, 1H)
  • CF₃: δ Not observed (fluorine coupling in ¹⁹F NMR)
  • Methine CH: δ 3.12 (m, 1H)
• ¹⁹F NMR: Single peak at δ -62.5 ppm (trifluoromethyl)
• ¹³C NMR (125MHz): 19 distinct carbon signals
• FTIR: Amide N-H (3300 cm⁻¹), C=O (1660 cm⁻¹), C-F (1120 cm⁻¹)

Physical Testing:

• Water content: <0.5% (Karl Fischer)
• Heavy metals: <10 ppm (ICP-MS)
• Residue on ignition: <0.1%

Research Applications & Scientific Significance

MK-2866 capsules serve critical functions in multiple research disciplines:

Androgen Receptor Pharmacology:

• AR binding affinity determination (competition vs. [³H]-DHT)
• Coactivator recruitment assays (SRC-1, GRIP1)
• Tissue-selective gene expression (muscle vs. prostate)
• Partial agonist characterization (transcriptional activity)

Musculoskeletal Research:

• Muscle atrophy models (denervation, disuse, cancer cachexia)
• Sarcopenia studies (age-related muscle loss)
• Bone density and osteoporosis research
• Fracture healing acceleration models

Metabolic Studies:

• Body composition analysis (lean mass vs. fat mass)
• Glucose homeostasis (insulin sensitivity)
• Lipid metabolism (cholesterol, triglycerides)
• Energy expenditure quantification

Comparative SARM Research:

• Structure-activity relationships (SARM scaffold comparisons)
• Selectivity profiling (vs. other SARMs: LGD-4033, RAD-140, S4)
• Efficacy comparisons (vs. testosterone, DHT)
• Safety profiling (hepatotoxicity, cardiovascular)

Clinical Translation Research:

• Dose-response relationships ( Phase I/II modeling)
• Pharmacokinetic studies (t½ ~24 hours, oral bioavailability ~90%)
• Therapeutic window determination
• Biomarker identification (IGF-1, testosterone, SHBG)

Global Distribution & Discrete Procurement

BioSynLab provides secure, compliant distribution:

Packaging Specifications:

• Primary: Hard gelatin capsules in HDPE bottles or blister packs
• Secondary: Tamper-evident seals, desiccant chambers
• Tertiary: Discrete unmarked shipping containers

Shipping Options:

• Standard: Ambient temperature, 5-7 days
• Express: Tracked courier, 2-3 days
• Discrete: No product identifiers, generic return addresses

Service Coverage:

United Kingdom: London, Manchester, Birmingham, Leeds, Glasgow, Liverpool, Sheffield, Bristol, Edinburgh, Cardiff, Belfast, Nottingham, Leicester.

European Union: Berlin, Hamburg, Munich, Cologne, Frankfurt, Amsterdam, Rotterdam, Paris, Lyon, Barcelona, Madrid, Rome, Milan, Vienna, Brussels, Prague, Warsaw.

North America: New York, Los Angeles, Chicago, Houston, Philadelphia, San Antonio, San Diego, Dallas, San Jose, Austin, Toronto, Vancouver.